Induction of cyclooxygenase-2 expression by prostaglandin E2 stimulation of the prostanoid EP4 receptor via coupling to Gαi and transactivation of the epidermal growth factor receptor in HCA-7 human colon cancer cells

Kenji Yoshida, Hiromichi Fujino, Sho Otake, Naofumi Seira, John W Regan, Toshihiko Murayama

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Increased expressions of cyclooxygenase-2 (COX-2) and its downstream metabolite, prostaglandin E2 (PGE2), are well documented events in the development of colorectal cancer. Interestingly, PGE2 itself can induce the expression of COX-2 thereby creating the potential for positive feedback. Although evidence for such a positive feedback has been previously described, the specific E-type prostanoid (EP) receptor subtype that mediates this response, as well as the relevant signaling pathways, remain unclear. We now report that the PGE2 stimulated induction of COX-2 expression in human colon cancer HCA-7 cells is mediated by activation of the prostanoid EP4 receptor subtype and is followed by coupling of the receptor to Gαi and the activation of phosphatidylinositol 3-kinase. Subsequent activation of metalloproteinases releases membrane bound heparin-binding epidermal growth factor-like growth factor resulting in the transactivation of epidermal growth factor receptors and the activation of the extracellular signal-regulated kinases and induction of COX-2 expression. This induction of COX-2 expression by PGE2 stimulation of the prostanoid EP4 receptor may underlie the upregulation of COX-2 during colorectal cancer and appears to be an early event in the process of tumorigenesis.

Original languageEnglish (US)
Pages (from-to)408-417
Number of pages10
JournalEuropean Journal of Pharmacology
Volume718
Issue number1-3
DOIs
StatePublished - 2013

Fingerprint

Receptors, Prostaglandin E, EP4 Subtype
Cyclooxygenase 2
Epidermal Growth Factor Receptor
Dinoprostone
Colonic Neoplasms
Transcriptional Activation
Colorectal Neoplasms
Phosphatidylinositol 3-Kinase
Extracellular Signal-Regulated MAP Kinases
Metalloproteases
Epidermal Growth Factor
Prostaglandins
Heparin
Intercellular Signaling Peptides and Proteins
Carcinogenesis
Up-Regulation
Membranes

Keywords

  • Colon cancer
  • Cyclooxygenase-2
  • G
  • Human prostanoid EP4 receptor
  • PGE
  • Phosphatidylinositol 3-kinase
  • Prostaglandin E

ASJC Scopus subject areas

  • Pharmacology

Cite this

Induction of cyclooxygenase-2 expression by prostaglandin E2 stimulation of the prostanoid EP4 receptor via coupling to Gαi and transactivation of the epidermal growth factor receptor in HCA-7 human colon cancer cells. / Yoshida, Kenji; Fujino, Hiromichi; Otake, Sho; Seira, Naofumi; Regan, John W; Murayama, Toshihiko.

In: European Journal of Pharmacology, Vol. 718, No. 1-3, 2013, p. 408-417.

Research output: Contribution to journalArticle

@article{fff2642d93194193a6d3ad7a54985ab8,
title = "Induction of cyclooxygenase-2 expression by prostaglandin E2 stimulation of the prostanoid EP4 receptor via coupling to Gαi and transactivation of the epidermal growth factor receptor in HCA-7 human colon cancer cells",
abstract = "Increased expressions of cyclooxygenase-2 (COX-2) and its downstream metabolite, prostaglandin E2 (PGE2), are well documented events in the development of colorectal cancer. Interestingly, PGE2 itself can induce the expression of COX-2 thereby creating the potential for positive feedback. Although evidence for such a positive feedback has been previously described, the specific E-type prostanoid (EP) receptor subtype that mediates this response, as well as the relevant signaling pathways, remain unclear. We now report that the PGE2 stimulated induction of COX-2 expression in human colon cancer HCA-7 cells is mediated by activation of the prostanoid EP4 receptor subtype and is followed by coupling of the receptor to Gαi and the activation of phosphatidylinositol 3-kinase. Subsequent activation of metalloproteinases releases membrane bound heparin-binding epidermal growth factor-like growth factor resulting in the transactivation of epidermal growth factor receptors and the activation of the extracellular signal-regulated kinases and induction of COX-2 expression. This induction of COX-2 expression by PGE2 stimulation of the prostanoid EP4 receptor may underlie the upregulation of COX-2 during colorectal cancer and appears to be an early event in the process of tumorigenesis.",
keywords = "Colon cancer, Cyclooxygenase-2, G, Human prostanoid EP4 receptor, PGE, Phosphatidylinositol 3-kinase, Prostaglandin E",
author = "Kenji Yoshida and Hiromichi Fujino and Sho Otake and Naofumi Seira and Regan, {John W} and Toshihiko Murayama",
year = "2013",
doi = "10.1016/j.ejphar.2013.08.002",
language = "English (US)",
volume = "718",
pages = "408--417",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Induction of cyclooxygenase-2 expression by prostaglandin E2 stimulation of the prostanoid EP4 receptor via coupling to Gαi and transactivation of the epidermal growth factor receptor in HCA-7 human colon cancer cells

AU - Yoshida, Kenji

AU - Fujino, Hiromichi

AU - Otake, Sho

AU - Seira, Naofumi

AU - Regan, John W

AU - Murayama, Toshihiko

PY - 2013

Y1 - 2013

N2 - Increased expressions of cyclooxygenase-2 (COX-2) and its downstream metabolite, prostaglandin E2 (PGE2), are well documented events in the development of colorectal cancer. Interestingly, PGE2 itself can induce the expression of COX-2 thereby creating the potential for positive feedback. Although evidence for such a positive feedback has been previously described, the specific E-type prostanoid (EP) receptor subtype that mediates this response, as well as the relevant signaling pathways, remain unclear. We now report that the PGE2 stimulated induction of COX-2 expression in human colon cancer HCA-7 cells is mediated by activation of the prostanoid EP4 receptor subtype and is followed by coupling of the receptor to Gαi and the activation of phosphatidylinositol 3-kinase. Subsequent activation of metalloproteinases releases membrane bound heparin-binding epidermal growth factor-like growth factor resulting in the transactivation of epidermal growth factor receptors and the activation of the extracellular signal-regulated kinases and induction of COX-2 expression. This induction of COX-2 expression by PGE2 stimulation of the prostanoid EP4 receptor may underlie the upregulation of COX-2 during colorectal cancer and appears to be an early event in the process of tumorigenesis.

AB - Increased expressions of cyclooxygenase-2 (COX-2) and its downstream metabolite, prostaglandin E2 (PGE2), are well documented events in the development of colorectal cancer. Interestingly, PGE2 itself can induce the expression of COX-2 thereby creating the potential for positive feedback. Although evidence for such a positive feedback has been previously described, the specific E-type prostanoid (EP) receptor subtype that mediates this response, as well as the relevant signaling pathways, remain unclear. We now report that the PGE2 stimulated induction of COX-2 expression in human colon cancer HCA-7 cells is mediated by activation of the prostanoid EP4 receptor subtype and is followed by coupling of the receptor to Gαi and the activation of phosphatidylinositol 3-kinase. Subsequent activation of metalloproteinases releases membrane bound heparin-binding epidermal growth factor-like growth factor resulting in the transactivation of epidermal growth factor receptors and the activation of the extracellular signal-regulated kinases and induction of COX-2 expression. This induction of COX-2 expression by PGE2 stimulation of the prostanoid EP4 receptor may underlie the upregulation of COX-2 during colorectal cancer and appears to be an early event in the process of tumorigenesis.

KW - Colon cancer

KW - Cyclooxygenase-2

KW - G

KW - Human prostanoid EP4 receptor

KW - PGE

KW - Phosphatidylinositol 3-kinase

KW - Prostaglandin E

UR - http://www.scopus.com/inward/record.url?scp=84887090740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887090740&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2013.08.002

DO - 10.1016/j.ejphar.2013.08.002

M3 - Article

C2 - 23973650

AN - SCOPUS:84887090740

VL - 718

SP - 408

EP - 417

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -